1. At a Glance
Jubilant Ingrevia — the not-so-silent spin-off from the Jubilant empire — is finally looking like that college topper who spent the first few years finding himself in Goa but now has returned to the syllabus with vengeance.
At ₹677 a pop, with a market cap of ₹10,805 crore, this life science chemicals cocktail-maker is trading at 37.5x earnings and 19x EV/EBITDA, which basically means Mr. Market is paying champagne prices for ethanol returns — but hang on, the numbers are starting to fizz.
In Q2FY26, the company’s sales touched ₹1,121 crore (up 7.2% QoQ), while PAT hit ₹69.5 crore, a neat 17.8% jump. The EBITDA margin is hanging around 12%, like a tired chemistry professor still refusing to retire. Debt stands at ₹764 crore (D/E 0.26x), and ROCE is improving at 11.2%. But the real story is the Capex – a ₹2,000-2,500 crore expansion plan to fuel CDMO and fine chemicals, their version of Avengers Assemble.
So, what happens when a midcap chemical veteran tries to reinvent itself as a high-margin global player? Let’s open the lab report.
2. Introduction – The Chemistry of Comebacks
Once upon a time, there was a company called Jubilant Life Sciences — a jack of all trades dabbling in pharma, chemicals, and whatever else smelled profitable. Then came 2021, the demerger — and thus was born Jubilant Ingrevia, the prodigal child, supposedly leaner, focused, and ready to rock the specialty chemicals world.
But life post-demerger was like post-breakup blues — revenue dipped 5% in three years, Chinese dumping hit the chemicals segment harder than IPL memes hit Twitter, and the ROE decided to take a power nap at 9%. Investors who thought they were buying “India’s DSM” ended up attending a lab practical in patience.
Yet FY25 and FY26 seem to be the plot twist. Margins are climbing, exports are reviving, CDMO orders are coming in, and the company’s Vitamin B3 and Acetic Anhydride businesses are finding new shine in a post-China world. The management’s grand ₹2,000 crore capex — that’s not just expense, that’s therapy — aimed at MPPs (Multi-Purpose Plants), specialty nutrition, and electronic chemicals.
The comeback script is ready. Now, will the molecules cooperate?
3. Business Model – WTF Do They Even Do?
If chemistry bored you in school, Jubilant Ingrevia is the revenge of that subject. The company is basically three businesses living under one molecular roof:
a) Speciality Chemicals – This is where the company mixes chemistry with capitalism. It makes pyridine and picolines (no, not Pokémon names), diketene derivatives, fine chemicals, and runs a CDMO (Custom Development & Manufacturing) business for pharma and agrochemical giants. They serve 15 of the top 20 global pharma players and 7 of the top 10 agrochemical ones — a global elite clientele that probably has more NDAs than Bollywood PR agencies.
b) Nutrition & Health Solutions – Think vitamins for humans, animals, and apparently, also for your portfolio. They’re the #2 global player in Vitamin B3 and #1 in Vitamin B4 in India. If you’ve had eggs or energy drinks lately, there’s a decent chance you’ve digested some Jubilant chemistry.
c) Chemical Intermediates – The legacy base. Stuff like Acetic Anhydride, Ethyl
